Literature DB >> 16091581

Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy.

Kelly C Linden1, Carrie L DeHaan, Yuan Zhang, Sylwia Glowacka, Alison J Cox, Darren J Kelly, Suzanne Rogers.   

Abstract

Renal tubular glucose reabsorption is mediated by facilitative glucose transporter (GLUT) proteins and energy-dependent sodium glucose luminal transporters. Glucose transport in the diabetic kidney is upregulated and has been implicated in the pathogenesis of progressive diabetic nephropathy. Hyperglycemia, hypertension, and activation of the renin-angiotensin system are believed important in the development of the disease. The present study examines the renal expression of the facilitative glucose transporters GLUT1 and GLUT12 in rat models of diabetic nephropathy. Sprague-Dawley and transgenic (mRen-2)27 rats received either streptozotocin-induced diabetes or vehicle. GLUT12 expression and localization were determined by immunohistochemistry, immunoblotting, in situ hybridization, and confocal immunofluorescence. GLUT1 immunolabeling was detected on the basolateral membrane throughout the nephron. GLUT12 was localized to the distal tubules and collecting ducts. A significant increase in GLUT12 immunolabeling was measured in Ren-2 controls and Ren-2 diabetic animals compared with Sprague-Dawley controls. GLUT12 expression was higher in Ren-2 diabetic compared with Sprague-Dawley diabetic rats. Long-term diabetes resulted in significant increases in GLUT1 levels in the renal proximal tubules and expression was higher in Ren-2 diabetic than Sprague-Dawley diabetic rats. GLUT12 protein was localized to the cytoplasm and to the apical membrane of human and rat distal tubules and collecting ducts. The apical localization of GLUT12 in the distal tubules and collecting ducts suggests that it could contribute to additional glucose reabsorption in the late nephron. Levels of both GLUT1 and GLUT12 are elevated in animal models of hypertension and diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091581     DOI: 10.1152/ajprenal.00237.2004

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  19 in total

1.  Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells.

Authors:  Rekha Yesudas; Russell Snyder; Thomas Abbruscato; Thomas Thekkumkara
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

2.  Huangqi (astragalus) decoction ameliorates diabetic nephropathy via IRS1-PI3K-GLUT signaling pathway.

Authors:  Xia Chen; Hao Wang; Minqian Jiang; Jie Zhao; Chunling Fan; Yunman Wang; Wen Peng
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 3.  The facilitative glucose transporter GLUT12: what do we know and what would we like to know?

Authors:  Jonai Pujol-Giménez; Jaione Barrenetxe; Pedro González-Muniesa; Maria Pilar Lostao
Journal:  J Physiol Biochem       Date:  2012-10-03       Impact factor: 4.158

4.  GLUT1 enhances mTOR activity independently of TSC2 and AMPK.

Authors:  Carolyn L Buller; Charles W Heilig; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2011-05-25

5.  MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes.

Authors:  Nirmalya Dey; Falguni Das; Meenalakshmi M Mariappan; Chandi Charan Mandal; Nandini Ghosh-Choudhury; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

6.  Glucose dilates renal afferent arterioles via glucose transporter-1.

Authors:  Jie Zhang; Shan Jiang; Jin Wei; Kay-Pong Yip; Lei Wang; En Yin Lai; Ruisheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2018-03-07

7.  Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis.

Authors:  Youli Wang; Kathleen Heilig; Thomas Saunders; Andrew Minto; Dilip K Deb; Anthony Chang; Frank Brosius; Carmela Monteiro; Charles W Heilig
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

8.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Authors:  Shizuka Aritomi; Kazumi Niinuma; Tetsuya Ogawa; Tomoyuki Konda; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-17       Impact factor: 2.801

9.  Over-expression of muscle glycogen synthase in human diabetic nephropathy.

Authors:  Rodrigo Gatica; Romina Bertinat; Pamela Silva; Pamela Kairath; Felipe Slebe; Fabián Pardo; María J Ramírez; Juan C Slebe; José M Campistol; Francisco Nualart; Carme Caelles; Alejandro J Yáñez
Journal:  Histochem Cell Biol       Date:  2014-11-05       Impact factor: 4.304

10.  Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice.

Authors:  Richard D Beger; Deborah K Hansen; Laura K Schnackenberg; Brandie M Cross; Javad J Fatollahi; F Tracy Lagunero; Zoltan Sarnyai; Laszlo G Boros
Journal:  Metabolomics       Date:  2009-03-31       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.